Online inquiry

IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5535MR)

This product GTTS-WQ5535MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD40LG gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000074.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 959
UniProt ID P29965
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5535MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6641MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DI-17E6
GTTS-WQ3429MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ9825MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ11093MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ4503MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-936557
GTTS-WQ780MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ15983MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ6154MR IVTScrip™ mRNA-Anti-CTLA4, CP-675(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CP-675
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW